Bayer Cropscience Gmbh

Merck + Co., Inc.

Colleen S Taylor

Patrick Schwientek

Bjorn A Traag

Jeremy Beau

Daniel M Joo

Michel M Chartrain

Hong Zhu

Gerald F Bills

Daniel Richard Sidler

Norihiro Ikemoto

Andreas Goertz

Brian Heimbuch

Christopher Roberge

Magalie Guilhabert-Goya

Jonathan S Margolis

Barbara A Jackey

Jorge I Jimenez

Yan Li

Donglan Tian

Adam Newman

Chad Kimmelshue

The present invention provides a composition comprising a biologically pure culture of asp. strain or a cell-free preparation thereof comprising a fusaricidin and a tridecaptin; wherein the fusaricidin is produced with a fusaricidin synthetase gene of fusA encoded by a DNA sequence exhibiting at least 90.5% sequence identity to SEQ ID NO: 3; and the tridecaptin is produced with a nonribosomal peptide synthetase (NRPS) gene of triE encoded by a DNA sequence exhibiting at least 90.0% sequence identity to SEQ ID NO: 7. Also provided are methods of treating an agricultural plant to control a disease and methods of increasing the vigor and/or crop yield of an agricultural plant with the disclosed compositions.

Paenibacillus strains and methods for their use

The present invention relates to a composition comprising a biologically pure culture of a fungicidalsp. strain comprising a variant fusaricidin synthetase lacking a functional adenylation domain in the third module. The present invention also provides a composition comprising a biologically pure culture of a fungicidalsp. strain or a cell-free extract thereof comprising at least one Paeniserine and at least one Paeniprolixin. Also provided are isolated compounds and methods of treating a plant to control a plant disease with the disclosed compositions and compounds.

Paenibacillus strain, antifungal compounds, and methods for their use

The present invention provides a method of enriching a lipopeptide in a microbial cell culture, the method comprising mixing an amphiphilic sulfonate and/or an amphiphilic sulfate with the cell culture to induce the formation of aggregates containing the lipopeptide, centrifuging the cell culture to generate a supernatant fraction and a pellet fraction, separating the pellet fraction from the supernatant fraction, and mixing the pellet fraction with a polyoxyethylene glycol alkyl ether to release the lipopeptide from the aggregates. Also provided is a method of purifying an exopolysaccharide from a microbial cell culture, the method comprising mixing an amphiphilic sulfonate and/or an amphiphilic sulfate with the cell culture to induce the formation of aggregates, centrifuging the cell culture to generate a supernatant fraction and a pellet fraction, separating the supernatant fraction from the pellet fraction, adding alcohol to the supernatant fraction to precipitate the exopolysaccharide; and removing the precipitated exopolysaccharide from the supernatant fraction.

Method of purifying antifungal compounds and exopolysaccharides from a microbial cell culture

strain, antifungal compounds, and methods for their use

[object Object]

The present invention provides an insecticidal fermentation broth of an actinomycete, where the fermentation broth contains an optimized ratio of active dunaimycins to inactive dunaimycins.

Insecticidal fermentation broth from actinomycetes containing enhanced ratio of active to inactive dunaimycins

This invention relates to crystalline pharmaceutically acceptable salts of an alpha 1a adrenergic receptor antagonist, Compound A, which are useful in the treatment of benign prostatic hyperplasia. Pharmaceutical compositions employing the crystalline salts, and processes for making and using the crystalline salts and pharmaceutical compositions of Compound A are also disclosed. This invention further relates to a process for obtaining enantiomerically pure intermediate useful for the synthesis of end product alpha 1a adrenergic receptor antagonists. The end product compounds are useful for the treatment of benign prostatic hyperplasia and for relaxing lower urinary tract tissue. The invention also relates to a process for preparing a class of dihydropyrimidinone compounds of which Compound A is a member, wherein the process involves deprotonating a dihydropyrimidinone compound and then coupling the deprotonated derivative with a primary amine.

Enzymatic process of making alpha 1a adrenergic receptor antagonists using protease

A method for preparing (1S)-amino-(2R)-indandiol substantially free of its stereoisomers is presented. The method comprises culturing indene with Rhodococcus sp. ATCC 55805, recovering the indandiol and subjecting the indandiol to chiral specific crystallization, treatment with strong acid and reverse ion pair extraction.

Conversion of indene to (1S)-amino-(2R)-indanol free of any steroisomer

Growing community of inventors

Folsom, CA, United States of America

Colleen S Taylor